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1. Introduction
The incidence of brain tumors and other types of cancer have been evidently increasing during
the last few decades. Due to the well documented fact that the cancer cells are under high levels
of oxidative stress, the relevance between oxidative stress and cancer has been the main topic
of intense discourse (Powis & Baker, 1997; Pervaiz & Clement, 2004). Elevated levels of intrinsic
oxidative stress has been emphasized in different types of tumors, possibly due to the
clustering of factors such as enhanced metabolism, mitochondrial mutation, inflammation and
cytokines (Mumper, 2009). Cellular damage on account of oxidative stress has been indicated
in a range of disorders such as cancer (Floyd, 1990) diabetes mellitus (Dandona, et al.,1996),
atherosclerosis (Valko, et al., 2007), neurodegenerative disorders such as Alzheimer’s disease
and Parkinson’s disease (Jenner, 1997) autoimmune disorders such as arthritis and has also
been indicated to be involved in aging (Ames & Shigenaga, 1992)
Oxidation is a natural process of cellular metabolism, but oxidation is what creates these
destructive reactive oxygen species (ROS). ROS are constantly produced during oxidative
metabolism and can  have  deleterious  effects  on  cell  function  and viability  due  to  their
ability to induce damage to the cells.  The formation of ROS is a consequence of aerobic
metabolism (Castro,  2001).  ROS are generated in many compartments and by numerous
enzymes in cells (Fig. 1).
In normal conditions, the countenance in the intracellular ROS levels is maintained with the
contribution of antioxidant scavenging systems and defense components. Yet, in some
disorders such as cancer, the balance between the ROS and the antioxidant status falls off.
Brain tissue also displays higher susceptibility to oxygen and glucose necessity, which are
required to support normal function through glycolysis and oxidative phosphorylation thus
the brain is particularly susceptible to oxidative damage since does not have much antioxidant
storage. Additionally, the brain has a high amount of fatty acids. All these attributes lead to
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brain cell damage. Thereby human brain encounters intense percentage of oxygen consump‐
tion, eventually generates an excessive amount of reactive oxygen species (ROS) when
compared with other tissues.
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Figure 1. Sources of reactive oxygen species in the human body
Oxidative stress can be defined as the disturbance in the oxidant-antioxidant balance
(Chandra, et al., 2000). The cancer cells exposed to oxidative stress tend to heavily interpret
adaptation mechanisms and may deplete cellular antioxidant capacity. The generated exces‐
sive ROS cannot be neutralized by cellular antioxidants and oxidative stress endures (Pervaiz,
2006). The redox status related to the production of intracellular ROS in cancer cells has also
been denoted to control the aggression of cancer cells. The reason of the induced oxidative
stress in cancer cells is a result of the lower levels of antioxidant enzymes such as SOD,
glutathione peroxidase, glutathione reductase, and catalase (Anshul, 2009). The reduced ROS
combout is known in conjunction with tumor growth and metastasis.
The enhanced oxidative stress can lead to modification of cellular targets and induce cell
damage and death. Nuclear and mitochondrial DNA single strand breaks, mitochondrial
inner membrane damage resulting with the loss of cellular ATP storage and initiation of
lipid peroxidation in membrane phospholipids can be seen (Farber, et al.,  1990). The cell
damage and the following deficiency in cellular repair processes due to the constant oxi‐
dative damage are correlated with carcinogenesis( Behrend, et al.,  2003; Federico, et al.,
Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors524
2007;  Nair & Nair,  2007).  Such as,  guanine nucleotide base oxidation in DNA results  in
the formation of 8- hydroxy-2-deoxyguanosine (8-OHdG), which alters DNA and eventu‐
ates  as  mutagenesis  and  cause  carcinogenesis  (Gate,  et  al.,  1999).  ROS  interaction  with
DNA results in fragmentation with the loss of bases and causes DNA strand breaks (Im‐
lay,  1988;  Farber,  et  al.,  1990;  Farber,  1994).  When  DNA  strand  breaks  accumulates  in
cells, this can lead oncogenic transformation depending on the intensity of cellular repair
processes  (Federico,  et  al.,  2007).  At  this  level,  cells  exposed to  excessive ROS stress  ei‐
ther undergo apoptosis or in some cases the cells start to proliferate and thus are irrever‐
sibly  turn  into  malignant  cells  (Fruehauf  &  Meyskens,  1997)  and  maintain  excessive
oxidative  stress  compared to  normal  cells.  Thus  the  strategy  of  producing  further  ROS
stress in malignant cells could be a successful anti-cancer strategy (Anshul, 2009).
On the other hand, ROS also subserve for the regulation of cellular functions and normal
metabolism (Poli,  et  al.,  2004).  Adversely,  low concentrations  of  ROS serve a  variety  of
important  cellular  functions  such  as  the  activation  and  modulation  of  the  signal  trans‐
duction  pathways  (Monteino  &  Stern,  1996),  modulation  of  the  activities  of  the  redox
sensitive  transcription  factors  (Li,  et  al.,  1998;  Oberley,  2002)  regulation  of  apoptosis
(Nulton-Persson,  2001;  Fang  &  Iyer,  2007)  and  the  regulation  of  mitochondrial  enzyme
activities  (Nulton-Persson,  2001;  Oberley,  2002).  Increased  ROS  production  is  well  dis‐
played in transformed cells (Toyokuni, et al., 1995; Burdon, 1995; Storz, 2005; Kryston, et
al.,  2011) and growing evidence suggests that ROS act as second messengers in intracel‐
lular signaling pathways (Liou & Storz, 2010).
Recently, oxidative stress has been related with the etiology and the prospective treatment of
cancer (Powis & Baker, 1997; Pervaiz & Clement, 2004). Cells have developed a number of
antioxidant defense systems to confront the hazardous effects of endogenous ROS production
and accumulation to protect against cellular oxidative damage. Antioxidants in the cells form
a heterogeneous group including low molecular weight substances which are water or lipid
soluble, being inclusive in the body through nutrition, also a number of endogenous metabo‐
lites own antioxidant activities.
Malignant gliomas account for the most diagnosed primary brain cancers (Behrend, et al.,
2003). Despite of exquisite treatment approaches the prognosis remains poor. There is a well-
documented association between increased consumption of antioxidants and decreased
incidence of cancer. Antioxidant supplements are recommended as part of a cancer prevention
diet. Even though cells have endogenous antioxidant enzymes, most human cancer cells have
decreased antioxidant enzyme levels compared to their normal tissue counterparts. It is found
that; cruciferous vegetables such as broccoli, horseradish, brussels, decreased the risk of
anaplastic astrocytomas which is a type of aggressively growing brain tumor. One of the
important functions of apoptosis is disposing of preneoplastic and neoplastic cells which
appears when a damage or malfunction is recognized and signaling cascades are initiated so
caspases and endonucleases that kill the cell are activated. In cell suicide, the signaling cascade
avails ROS as messenger molecules. Thats why antioxidants are ascendant in the inhibition of
apoptosis. So, the removal of antioxidants from the diet can be suggested as this may enhance
apoptosis and inhibit tumor growth. The tumor cell survives in an ROS rich environment
The Stance of Antioxidants in Brain Tumors
http://dx.doi.org/10.5772/54791
525
depending on the overexpression of antioxidant enzymes and the excessive levels of nonen‐
zymatic antioxidant scavengers. A range of complementary and alternative therapies can be
inclusive for the treatment of brain cancer. Nutrients and herbs are believed to protect against
side effects of conventional therapies, they may also enhance chemotherapy and support
anticancer activities. At that, normal cells protect themselves when exposed to high doses of
antioxidants while cancer cells can not adapt and they suffer damage caused by the antioxi‐
dants. Thus, high doses of antioxidants may be toxic to cancer cells but not to normal cells.
Antioxidants which are active in the brain tissue, can cross the blood brain barrier and prevent
oxidative damage, so this can also be taken into consideration as a good treatment and
prevention strategy of brain cancer.
2. The redox status of the brain
Brain is considered enormously vulnerable to oxidative damage so is the target for oxidative
stress damaging effects than the other tissues. One of the reasons is its having high oxygen
consumption (Sah, et al., 2002) and this is around 20% of the total metabolic activity (Dal-Pizzol,
et al., 2000). Also, the brain tissue contains much amounts of polyunsaturated fatty acids, which
are particularly sensitive to free radical attacks and prooxidative transition metals such as high
levels of iron which is a triggering factor in lipid peroxidation of the cell membranes and also
the brain has a comparatively low antioxidant capacity (Sies, 1993; Bellissimo, et al. 2001;
Freitas, et al., 2004) and glucose deprivation, which are needed to support normal metabolic
functions through glycolysis and oxidative phosphorylation.
Massive neuronal death is the outcome of the secondary injury response, creating an excessive
pool of ROS, which triggers a cascade of reactive oxygen chain reactions. The free metal
concentrations are also controlled in the nervous system by transport proteins such as ferritin
(Sies, 1993) and this limits the non-enzymatic catalysis of hydroxyl radical formation. The
nervous system contains antioxidant enzymes; including Cu/Zn- and Mn dependent SOD and
GPx which are expressed in higher quantities than CAT (Shivakumar et al., 1991; Hussain et
al., 1995). It was shown that the zinc, iron and selenium concentrations were found significantly
lower in cancer patients and the copper concentrations were found to be either elevated or
significantly elevated, as 2-3 fold, when compared to age matched samples of normal tissues
(Kuo, et al., 2002; Zuo, et al., 2006). It has been also shown that the Cu/Zn, Cu/Se and Cu/Fe
ratios were found higher in cancer patients when compared to normal subjects.
Cancer  cells  display  increased glycolysis  rate  combined with  a  reduced respiration  rate
(Spitz, 2000). The enhanced requirements for ATP; generates oxygen free radicals and this
causes oxidative stress conditions to come out which eventually promotes cell death. Neu‐
rons and cancer cells consume glucose as energy source to respond this issue and glycolyt‐
ic  metabolism  rules  over  in  tumor  cells.  The  release  of  cytochrome  c  couples  with  the
pentose phosphate pathway and this initiates cytochrome c mediated apoptosis (Vaughn
&Deshmukh, 2008). Caspase activation is initiated by cytochrome c when released from mi‐
tochondria during apoptosis.  So,  the cancer cells  and neurons control apoptosis through
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regulation of cytochrome c release,  while utilizing glucose as a source of energy (Dajas,
2012). This marked changes in metabolism have been shown to be related with increased
oxidative stress which is emphasized to be due to increased mitochondrial superoxide radi‐
cal production (Oberley, et al.,  1981). A more oxidizing redox status of the transforming
cell occurs and this streamlines immortalization, increases cell proliferation and supports
development of the malignant cell (Spitz, et al., 2000). In the initial steps of carcinogenesis,
a relatively prooxidant intracellular environment is developed and entails the mutation of
tumor suppression genes and the activation of the oncogenes. Thus, the loss of normal re‐
dox control in cell growth and development occurs (Blackburn, et al., 1999).
Oxidative stress in the brain is known to increase the glutamate release in the hippocampus,
and this affects ionic homeostasis and neurotransmission (Costa, 2004). The glutamate
receptors are activated subsequently so acidification occurs in neurons because of Ca2+ entry
and this can be associated with the death of central neurons (Reynolds & Hastings, 1995;
Bellisimo, et al., 2001). This countenance can be altered by increased ROS production or
decreased intracellular antioxidant defense systems (Tejada, et al., 2006).
Studies have been done to evaluate antioxidant enzyme activities in different types of brain
tumors. However, most studies have emphasized decreased levels of antioxidant enzymes and
vitamins in diverse malignancies (Rao, et al., 2000; Manju, et al., 2002; Gromadzinska, et al.,
2003) but still the results are inconsistent (Hennekens, et al., 1996).
2.1. Mitochondrial changes in tumor cells
Mitochondrial DNA is more vulnerable to mutation when compared with nuclear DNA.
Conversely to nuclear DNA, mitochondrial DNA is in close proximity to the electron transport
system where ROS are produced, and it doesn’t have any protective histones and chromatin
structure, also its repair capabilities are limited, and it doesn’t have any introns (Copeland, et
al., 2002). Many studies have established mitochondrial DNA changes in different cancer types
related to these features (Lu, et al., 1992; Savre-Train, et al., 1992; Polyak, et al., 1998; Modica,
et al., 2002; Modica, et al., 2007). Cancer specific mitochondrial DNA mutations have been
identified. Recent studies, associating the alterations in mitochondrial DNA and cancer risk,
suggest mitochondrial DNA changes during cancer development are more complicated than
estimated (Ebner, et al., 2011; Lam, et al. 2012).
Mitochondria are highly prospered with antioxidants such as GSH and antioxidant enzymes
such as superoxide dismutase and GPx, which exist on both sides of their membranes to
minimise oxidative stress in the organelle because mitochondria are the major zone of free
radical generation (Cadenas & Davies, 2000). Superoxide radicals are ascendantly detoxified
into hydrogen peroxide and into water by Cu/ZnSOD and MnSOD. The redox components of
the cell comprises mitochondrial redox indicators which are glutathione (GSH/GSSG),
thioredoxin (Trx/TrxR), glutaredoxin (Grx) and peroxiredoxin (Prx) systems dependent
merely on NADPH generation via reduction of NADP+ by mitochondria.
In some apparent cases, when mitochondrial oxidative stress increases, over generation of the
antioxidant defences above a certain threshold may lead to cell death. In normal cells, the same
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process would take longer to happen as mitochondrial oxidative stress would be in basal levels
and lower. Indeed, most of the anti tumor agents are known to act as prooxidant agents and
they disturb the mitochondrial respiratory chain and this leads to an increase in mitochondrial
oxidative stress levels (Chou, et al., 2004).
Relying on glycolysis other than oxidative phosphorylation for glucose oxidation and en‐
hanced usage of  glutamine as  an energy source  are  the  the  two common metabolic  re‐
programming  processes  in  cancer.  Excessive  upregulation  in  glutamine  consumption  is
seen in tumor cells which is a second shift  in energy metabolism (Barbosa,  et  al.,  2012).
Mitochondria  are  the  the  main  energy  producers  via  oxidative  phosphorylation  in  nor‐
mal  cells  and  they  produce  various  metabolic  intermediates,  and  they  mediate  various
apoptotic  pathways  (Weinberg  &  Chandel,  2009).  Mitochondria  exhibits  same  essential
roles  in  cancer  cells,  too.  Though,  mitochondria  undergo massive changes  during onco‐
genesis,  and this  mostly  result  with a  change in  the energy metabolism,  a  resistance to
apoptosis and enhanced ROS production.
Because the cancer cells have different metabolic and mitochondrial needs other than their
normal counterparts, metabolic and mitochondrial changes in cancer cells may suggest an
efficient and selective anti cancer therapy opportunity. This fact can be taken into consideration
when targeting tumor mitochondria in terms of therapy.
3. Antioxidant defence systems
ROS are detoxified by exhaustive antioxidant defence systems. When the balance between ROS
and antioxidant status is disturbed, cellular defences can be reeled causing an abnormal cell
growth and this leads in turn to tumor cell forming (Wang, et al., 2011). Mammalian cells have
developed a number of antioxidant defense systems to withstand the detrimental effects of
ROS and they protect against cellular oxidative damage (Aoyama, et al., 2008). Antioxidants
comprise of a highly heterogeneous group. They involve water or lipid soluble low molecular
weight substances and enzymes such as CAT, SOD, GPx and GR. Also, a number of endoge‐
nous metabolites have antioxidant activities (Table 1).
Superoxide dismutase enzyme decomposes superoxide radicals into H2O2 and O2. The most
important H2O2 scavenging enzymes and concerned proteins having antioxidant capacity
comprise CAT, GPx, GR enzymes associated with the synthesis of reduced GSH (Halliwell &
Gutteridge, 1996) and a group of cysteine containing proteins known as thioredoxins, thiore‐
doxin peroxidases (peroxiredoxins), and glutaredoxins (Kumar & Holmgren, 1999; Rhee, et
al., 1999; Powis, et al., 2000; Holmgren, 2000). When ROS production is enhanced, the antiox‐
idant scavenging capacity is disturbed and this results in the development of oxidative stress
which leads to tissue injury and apoptosis activation (Todorova, et al., 2004).
GSH is a low molecular weight thiol and it has a key role in maintaining the intracellu‐
lar  redox  balance.  Cellular  glutathione  appears  mainly  in  the  reduced  form  as  GSH,
while some of the total GSH exists in its oxidized disulfide form as GSSG. Depletion of
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GSH and an eventual  decrease in the GSH/GSSG ratio may be seen in oxidizing condi‐
tions,  yet  peroxidise  coupled  reactions  can  mediate  its  antioxidant  activity.  GSH  also
amends signaling pathways and some cellular events. In oxidative stress, GSH is deplet‐
ed hereby the GSH pool is  affected (Dickinson & Forman, 2002;  Circu & Aw, 2008; Bis‐
was & Rahman, 2009; Forman et al., 2009; Yuan & Kaplowitz, 2009).
Table 1. Antioxidants
Vitamin E, vitamin C and carotenoids can be defined as traditional antioxidant nutrients when
consumed with diet, also they have antioxidant and anti inflammatory properties along with
multiple other bioactive phytochemicals. The phytochemicals that includes phenolic acids and
their derivatives, flavonoids and different types of coumarins and tannins consist of a large
and heterogeneous group (Liu, 2004).
The phenolic compounds have recently been attracting attention conversely to antioxidant
vitamins and carotenoids (Gescher, et al., 2001) and still most have not been tested in placebo
controlled cancer prevention strudies. Curcumin, a phenolic acid derivative obtained from the
spice turmeric; resveratrol, a polyhydroxylated stilbene found in grapes ; and genistein, an
isoflavone readily isolated from soy have been pointed out for future studies (Gullet, et al.,
2010). These compounds are known to have antioxidant and anti inflammatory features
(Djuric, et al., 2001; Leu, et al., 2006; Brisdelli, et al., 2009), and they are implied as promising
in cancer prevention depending on in vitro and in vivo animal experiments (Sarkar, et al.,
2006; Sarkar, et al., 2010; Kelkel, et al., 2010; Patel, et al., 2010; Slusarz, et al., 2010). Resveratrol;
having a hydroxylated structure, is a well identified antioxidant. It can act both as free radical
scavenger and as metal chelator. Moreover, it also amends many enzymes in the regulation of
redox status which are CAT, SOD, GR, NADPH oxidase, xanthine oxidase and (Delmas et al.,
2005; Pervaiz & Holme, 2009). Flavonoids are polyphenols and isoflavones and anthocyani‐
dines as the subclasses of flavonoids. They have a strong antioxidant activity because of their
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free radical scavenging and metal chelating features, also they can interact with enzymatic and
non enzymatic mechanisms of the regulation of redox status (Heim et al., 2002; Laguerre et al.,
2007; Aron & Kennedy, 2008) (Fig.2).
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Figure 2. Antioxidant defence systems
Antioxidant molecules has been known as also beneficial in the induction of endogenous
protective antioxidant enzymes and in the modulation of various of cellular signaling path‐
ways (Valko et al., 2007). They can quickly oxidize spontaneously or induced by the biological
microenvironment.
Antioxidant enzymes can antagonize initiation and promotion steps of carcinogenesis and they
are reduced in cancer. Mitochondrial Mn-SOD is the most frequently decreasing enzyme and
this suggests that MnSOD may be a new type of tumour suppressor gene. On the other hand,
studies also suggest that the deficiency of the MnSOD enzyme activity depends on a defect in
the expression of the related gene. Transition metal ions such as Mn and Fe have been found
to be significantly lower in some tumours. It can be thought that, an impairment in the signal
transduction may cause the defect in the MnSOD gene expression in the early stage of
carcinogenesis (Mates, et al., 2000).
Studies are present implying low antioxidant status and enhanced oxidative stress in cancer pa‐
tients, even before chemotherapy starts. Low activities of Cu, Zn-SOD, MnSOD, CAT, and GPx
are shown in different types of tumor cells when compared with their normal counterparts
(Sykes, et al., 1978). Some studies show that administration of antineoplastic agents during can‐
cer therapy results in a higher level of oxidative stress rather than the stress induced by cancer it‐
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self (Conklin, 2000). Chemotherapeutic agents are thought to cause increase in ROS generation
by affecting mitochondrial respiration chain (Carew, et al., 2003; Pelicano, et al., 2003).
In chemotherapy, an increase in lipid peroxidation products and a significant decrease in some
plasma antioxidants such as Vitamin E, Vitamin C and carotenes are shown (Jeanne, et al.,
2003). The increase in oxidative stress during chemotherapy may exceed the oxidative defense
in cancer cells and this may initiate lipid peroxidation. Enhanced lipid peroxidation inhibits
cancer cell proliferation and intervenes chemotherapy. Thus, the antioxidant status in cancer
may play an important role in response to chemotherapy (Papageorgiou, et al., 2005).
3.1. Antioxidant status of the brain
Tumor cells frequently demonstrate a change in redox status. The alterations in the redox
environment enhancing oxidation can induce some of the factors that cause cell proliferation
and malignant transformation.
Elevated MnSOD levels were shown in the serum samples of neuroblastoma patients in a study
(Kawamura, et al., 1992). In recent studies, MnSOD was found to be associated with loss of
differentiation and increased clinical malignancy in neuroepithelial origined brain tumors
(Landriscina, et al., 1996; Ria, et al., 2001). MnSOD was found significantly positive in Grade
IV astrocytomas and medulloblastomas and negative in normal brain samples (Cobbs, et al.,
1996). It can be said that MnSOD is overexpressed in most brain tumor types and enhanced
MnSOD expression is related with a poor prognosis. MnSOD seems to be a tumor suppressor
in the proliferative stage. When tumor progresses more aggressive, MnSOD is upregulated.
MnSOD level positively correlates with increased metastasis so MnSOD has an oncogene role
(Hempel, et al., 2011; Dhar, et al., 2011). Increase in MnSOD level was seen during the
progression of different types of tumors, including brain, to the metastatic stage. Tumorigen‐
esis and metastasis are dependent on the levels of ROS. A cell having low levels of MnSOD is
vulnerable to oxidative stress then it may turn its progression to a tumor cell (Miriyala, et al.,
2012). Oxidative gene polymorphism and brain tumor risk seems associated, the increased risk
of glioma and meningioma type brain tumors were found to be related with variants in some
antioxidant enzyme genes (Rajaraman et al., 2008) and in a study, MnSOD tissue expression
is said to be a prognostic marker for glioblastoma (Park et al., 2009). SOD and GPx activities
showed a clear decrease proportionally with tumor malignancy, decrease of SOD activity with
the increasing grades of malignancy in brain tumors were implied.
The GSH redox cycle is  one of the most important antioxidative systems (Arrick & Na‐
than,  1984;  Mitchell,  et  al.,  1989;  Tedeschi,  et  al.,  1990).  GSH  is  a  primary  endogenous
neuroprotectant  for  the  brain.  GSH  protects  neuron  cells  from  lipid  peroxidation  and
brain  cells  from peroxynitrite  mediated oxidative  damage (Mark  et  al.,  1997;  Koppal  et
al., 1999). GSH, also has roles in the activation of transcription factors, DNA repair, regu‐
lation of enzyme activity and many other metabolic processes (Meister,  1995).  GSH syn‐
thesis,  usage  and export  are  the  processes  on  which  GSH homeostasis  is  dependent  in
glial  and neuronal  cells  (Anderson,  1998).  The main path for  chemotherapy metabolism
is through the conjugation of  the xenobiotic  with GSH. The removal  of  the GSH conju‐
gates from the cell  causes cellular GSH depletion and cellular redox balance disruption.
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GSH content  depends on the  substrate  availability  in  the  brain  and cysteine  is  the  rate
limiting substrate  for  neuronal  GSH biosynthesis  (Dringen,  et  al.,  1999).  Astrocytes  pro‐
vide neighbour cells the needed precursor amino acids for GSH synthesis (Hirrlinger, et
al., 2010). GSSG levels and the GSH/GSSG ratios can be restored through the GR mediat‐
ed pathway and flow of GSSG leaded by ATP dependent multi drug resistance-associat‐
ed  protein-1  (Mrp1)  transporter  in  astrocytes  and  neurons  (Hirrlinger,  et  al.,  2001;
Casagrande, et al.,  2002; Minich, et al.,  2006). Cultured astrocytes have high levels of re‐
duced  GSH  (Dringen  &  Hamprecht,  1998)  while  oligodendrocyte  precursors  have  high
levels  of  iron but  lower  levels  of  cellular  GSH when compared with astrocytes  or  neu‐
rons (Hussain & Juurlink, 1995; Thornburne & Juurlink, 1996), also oligodendrocyte pre‐
cursors are more sensitive to oxidative stress induced death in relation to GSH depletion
(Back, et al.,  1998). The GSH neutralization system has been shown also in the chemore‐
sistance of medulloblastoma (Colvin, et al.,  1993).  GSH and GST are prevalantly seen in
brain tissue, thus highly expressed in various primary brain tumors (Bredel,  2001).  GSH
content and GST expression was shown to be related to tumor response to nitrogen mus‐
tard therapy in human brain neoplasms (Evans, 1993). Also in another study it was indi‐
cated  that  the  cytotoxic  effect  of  BCNU  in  human  brain  tumor  cells  seems  associated
with the GSH content (Ali-Osman, et al., 1989). When GST isoenzymes in neoplastic and
non-neoplastic  astroglia  were  compared,  GST3  isoenzyme  was  seen  to  be  significantly
higher in tumors (Strange, et al.,  1992).  It  is said that GST expression levels in brain tu‐
mors  seems  in  association  with  the  tumor  histology  as  some  tumor  types  express  en‐
hanced levels but some show only slight rise or decrease when compared to normal cells
(Bredel, 2001). GST was found to be active in high levels in benign tumors such as men‐
ingioma but only two,  three folds higher compared to normal tissue but it  was slightly
increased  in  astrocytoma  (Matsumoto,  et  al.,  1992).  In  glioblastomas,  GSH  levels  were
found significantly lowered compared to normal tissue and merely elevated in meningio‐
ma (Kudo, et al., 1990).
It has been reported that elevation of intracellular GSH in tumour cells is associated with
mitogenic stimulation (Shaw & Chou,  1986),  that  GSH controls  the onset  of  tumour-cell
proliferation by regulating protein kinase C activity and intracellular pH (Terradez et al.,
1993).  GPx and GR decrease and protein oxidation increases in patients with glioblasto‐
ma  multiforme  and  transitional  meningioma  and  clear  different  oxidative  status  was
found in the two kinds of  tumors which represent  specially  one of  the most  malignant
and  most  benign  tumors  respectively  (Tanriverdi  et  al.,  2007)  and  it  was  shown  that
there is  a complex relationship between pro- and anti-apoptotic  molecules in glioblasto‐
ma  multiforme  pathogenesis,  thus  targeting  multiple  pathways  with  advanced  chemo‐
therapeutic  agents  or  radiotheraupetic  regimens  following  total  resections  might  be
helpful in patients with glioblastoma multiforme (Atukeren et al., 2010).
Antioxidant enzymes activity and concentration of nonenzymatic antioxidants in human
brain tumours were evaluated and significant  increases in all  enzyme activities  and de‐
creases in GSH and ascorbate levels were observed in brain tumors (Dudek et al., 2004) and
consistent differences in the levels of antioxidants in different types of brain tumors were
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emphasized in different studies (Hanimoglu et al., 2007; Tanriverdi et al., 2007; Tuzgen et
al., 2007; Zengin et al., 2009).
Serum β-carotene and α-tocopherol levels were found to be decreased in brain tumor pa‐
tients when compared to healthy subjects and also more less in malign tumors than the
benign types (Potishman, et al.,  1991; Zheng, et al, 1993; Palan, et al.,  1996). Few studies
have been done to compare the levels of these antioxidants in various histological types
of brain tumors. It was seen that β-carotene and α-tocopherol levels decreases when ma‐
lignancy  grade  increases  and the  decrease  was  found significant  for  oligodendroglioma
grade I-II,  glioblastoma multiforme and medulloblastoma.  The protective antioxidant ef‐
fects  of  these  two  vitamins  are  suggested  (Brigelius–Flohe,  et  al.,  2002).  The  decreased
antioxidant levels in brain tumor patients reflect the enhanced oxidative damage and in‐
creased cancer  developing possibility,  stating  the  role  of  antioxidants  in  cancer  preven‐
tion and role of oxidative injury as the of cancer (Aggarwal, et al., 2006).
4. The potential therapy in brain tumors regarding antioxidants
Antioxidant consumption is appraised if it can be a pledging therapeutic approach in pre‐
venting or minimizing neuronal oxidative damage (Halliwell, 2001; Uttara et al., 2009). A
relationship between excessive antioxidant consumption or high blood levels and a low cancer
incidence was found in many studies (Comstock, et al., 1992; Van den Brant, et al., 1992). Also
the importance of exogenous utilization of antioxidants with malignant glioma was shown in
various studies (Il'yasova et al., 2009; DeLorenze et al., 2010) yet antioxidant supplementation
by cancer patients during treatment is quite contentious. Indeed, a distinct declination or
recommendation for the simultaneous use of antioxidants with chemotherapy has not been
verified currently. The prospective antioxidant therapeutic approaches should involve either
inhibiting the ROS generation or scavenging. Recently, new strategies for antioxidant con‐
sumption have been studied carefully in order to maximize the influence and safety by
improving drug release and site specific targeting and to limit the adverse effects (Ratnam, et
al., 2006). Cancer cells’ having a a weak antioxidant defense system against oxidative stress
brings about a theoretical basis for the use of ROS generating systems in treatment (Laurent,
et al., 2005). Knowing that ROS have stimulating effects on tumor metastasis, the scavenging
of ROS is also a reasonable strategy to inhibit metastasis (Nishikawa, et al., 2006). Main
strategies as a potential treatment are the inhibition of the antioxidant enzymes and molecules
in cancer cells and the production of ROS leading to apoptosis (Lopez-Lazaro, 2007; McCarty,
et al., 2007). Recent studies involving ROS producing agents implied that their anti cancer and
cytotoxic effects are limited to cancer cells and no toxicity was seen in the surrounding normal
tissue (Yoshikawa, et al., 1995). The main mechanism of most chemotherapy drugs is via ROS
formation, but also free radicals production during chemotherapy is a serious side effects
(Block, et al., 2008). Interactions between chemotherapeutic compounds and antioxidants are
quite complicated and also the dose, the localization and the metabolism of the drug have
different effects. Furthermore, some antioxidants may act as oxidative molecules related with
their relative concentration (Badajatia, et al., 2010).
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The coexpression of catalase was shown to revert malignancy (Hempel, et al., 2011). The
overexpression of catalase protected cancer cell  from excessive peroxide production as a
result of combined menadione/ascorbate anticancer treatment (Glorieux, et  al.,  2011).  Al‐
so,  the  ability  of  ascorbate  to  radiosensitize  primary  human  glioblastoma  cells  and
mouse astrocytes and astrocytoma, was investigated and it  was concluded that pharma‐
cological concentrations of ascorbate radiosensitize glioblastoma primary cells more than
astrocytes  and this  can be  of  clinical  significance  in  therapeutic  approach (Herst,  et  al.,
2012). Besides, the activation of ferroptosis was shown to be resulted in the nonapoptotic
destruction of some cancer cells and inhibiting this process by ferrostatin-1 seems to pro‐
tect from neurodegeneration (Dixon, et al., 2012).
4.1. Targeting GSH pathway
GSH and the GSH related enzyme system might be a distinctive factor for the susceptibility of
several brain tumors to different chemotherapeutic agents (Backos, et al., 2012). Studies have
shown that drug resistance mediated by the GSH/GST system mediated drug resistance in
brain tumors might be the outcome of a change in a GSH related enzyme system and increased
GSH level (Ali-Osman, et al., 1989; Freidman, et al., 1992). Chemotherapeutics, thereby
chemoresistance, were shown to be related with increased cellular GSH content in brain tumor
cell lines (Ali-Osman, et al., 1989; Ali-Osman, et al., 1990). The increased GSH content is related
with tumor drug resistantance so exhaustion of cellular GSH can restore the sensitivity to the
cytotoxic effect of an anticancer agent (Barbosa, et al., 2012). So, it can be suggested that the
depletion of GSH content may increase the sensitivity to different chemotherapeutics. The
multidrug resistance-associated proteins (Mrp) can function as GSH, GSSG and GSH conjugate
carrier (Jedlitschky, et al., 1994; Muller, et al., 1994). Expelling these drug metabolites conju‐
gated with GSH ; changes the intracellular GSH levels distinctly. Mrps are considered to have
a role in resistance development to chemotherapeutics in most human brain tumors (Bredel &
Zentner, 2002). Mrp overexpression is associated with drug resistance in gliomas (Abe, et al.,
1998) and conversely with clinical outcome in neuroblastoma (Norris, et al., 1996). Astrocytes
have a potent GSH biosynthesis and antioxidant coupling is substantial in sustaining neuronal
GSH status and conserving neurons from ROS (Dringen R & Hirrlinger, 2003). Even the
concerned GST polymorphisms have been found to be associated with the survival (Kilburn,
et al., 2010), decreased GSH levels seems to play an important role in the increased sensitivity
of oligodendrogliomas to chemotherapy due to decreased GSH needed for detoxification. The
elevated iron levels in these cells also makes them daintily exquisite to ROS generation based
on chemotherapeutics (Yonezawa, et al., 1996). In a study, alantolactone which inhibits tumor
growth and triggers apoptosis and GSH depletion in glioblastoma, is suggested as a potential
lead compound for antiglioma therapy (Khan, et al., 2012).
4.2. Targeting mitochondria
Cancer cells have distinct metabolic and mitochondrial needs from their normal counterparts
so mitochondrial alterations in the context of metabolic reprogramming are an appealing target
for different therapeutic approaches. Most anti tumor agents act as prooxidants and they
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disturb mitochondrial respiratory chain and enhance mitochondrial oxidative stress (Chou, et
al., 2004). Considering that ROS have a role in activating signaling pathways thereby guiding
to metabolic remodeling; mitochondrial oriented antioxidants involving MitoQ may donate
to normalizing the metabolic phenotype in cancer cells. This antioxidant molecule has already
been indicated to diminish the hypoxic stimulation of ROS and to impair HIF-1alpha protein
by decreasing its transcriptional activity (Sanjuan-Pla, et al., 2005).
Occasionally, overloading the antioxidant system by increasing mitochondrial oxidative stress
over a certain threshold can be encountered leading to cell death. The same process would
take longer to come up in normal cells because the basal mitochondrial oxidative stress would
be lower. In a recent study, sulforaphane, having antioxidant and anti tumor features is
suggested to provide antitumor activity in malignant glioma cells via mitochondria and
caspase dependent pathways (Huang, et al., 2012).
4.3. Therapy via natural antioxidants
A great number of plants are good sources of phytochemical antioxidants and which have
been estimated having cancer fighting ability (Wang, et al., 2011). There is a reasonable
scientific and commercial interest in espialling new anti cancer molecules from natural sources,
involving secondary plant metabolites (Kinghorn, et al., 2003). Phytochemical antioxidants
existing in foods exhibit their anticancer properties via reducing ROS induced oxidative
damage by either scavenging or by increasing endogenous antioxidants (Du, et al., 2007).
Natural antioxidants have the ability to modulate signal transduction pathways by the
activating or inhibiting multiple redox sensitive transcription factors which is asserted as their
potential use as chemopreventive agents for therapy. They can act a part in initiation, promo‐
tion and progression stages of carcinogenesis to prevent cancer progress (Sporn, 1991).
Recently potential chemopreventive activities of dietary polyphenols was shown in most
studies (Thomasset, et al., 2007). The effects of flavonoids being natural polyphenolic antiox‐
idant compounds in brain development, neuroprotection and glial tumor formation are
mentioned and developing new therapeutic approaches was discussed (Nones et al.; 2010).
Epigallocatechin-3-gallate (EGCG) from green tea, curcumin from turmeric, and resveratrol
from grapes are some examples of polyphenols.
Resveratrol has the ability to block the activation of carcinogens and induce their detoxifi‐
cation, thus to prevent ROS damage and alleviate inflammatory responses and to reduce
the proliferation of cancer cells which reflect its chemopreventive property (Aggarwal, et
al., 2004; Shankar, et al., 2007). The chemotherapeutic potential of resveratrol is refered to
its blocking angiogenic and metastatic processes of tumor progression and relieving che‐
motherapy resistance (Aggarwal, et al., 2004; Fulda & Debatin, 2006). The potential thera‐
peutic  effect  of  resveratrol  being a  dietary phytochemical  antioxidant,  is  investigated in
glioma type brain tumors (Gangliano et al., 2010) and glioblastoma multiforme cells exhib‐
ited variable responses to resveratrol depending on the brain associated sulfonation activi‐
ty of the cells and resveratrol seemed to have value in glioblastoma treatment (Sun, et al.,
2012). Also the combination of resveratrol with alkylating agent temozolomide was shown
to improve the efficacy of chemotherapy for brain tumors (Herst, et al., 2012). EGCG also
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exhibited the same effect with temozolomide like as resveratrol in another study, in brain
tumor therapy (Chen, et  al.,  2011).  Curcumin as a polyphenol gets attention in blocking
brain tumor formation in a study. The chemopreventive and anticarcinogenic action of cur‐
cumin is shown and suggested as this might be due to its ability to inhibit proteins that ini‐
tiate protective signals (Purkayastha, et al., 2009).
Different  studies  implied  the  importance  of  using  nutritional  antioxidants.  Lycopene,
present in tomato,  was shown for its  potential  therapeutic  benefit  in the adjuvant man‐
agement of high grade gliomas (Puri et al., 2010). Gynostemma pentaphyllum extract se‐
lectively shifted H2O2 concentration in glioma tumor cells to toxic levels due to increased
SOD activity so can be suggested for cancer therapy (Schild et al., 2010) and the apoptot‐
ic  effect  of  γ-Mangostin in  Garcinia  mangostana fruit  was shown and it  was suggested
as a prospective anti brain tumor agent (Chang et al., 2010).
5. Conclusion
The incidence of brain tumors is obviously increasing recently. The occurance of ROS are the
inevitable outcome of the metabolism and they have important roles in many biochemical
processes but they must be precisely kept under control. Antioxidant molecules are that delay,
prevent, or remove the existing oxidative damage to a target molecule. The brain is quite
vulnerable to ROS damage because of its low antioxidant levels. To get over ROS damage, the
brain needs a sufficient supply of antioxidants and it seems convinent that working up with
ROS signaling pathways would provide a great neuroprotective effect. The development of
the suitable antioxidant compounds seems a challenging and pledging strategy for brain tumor
treatment but plenty of work has to be done to emphasize the exact role of antioxidants for
therapy in clinical use.
Adjusting the antioxidant dose and scheduling of the administration or combining different
antioxidants and exploring a more potent and specific antioxidant should be the main theme.
Also the preventive and therapeutic molecule should target multiple biochemical pathways
comprising the processes entailing malignancy and restrain the unwanted side effects and
toxicity in the normal tissue counterparts. In the same time should attend a beneficial task in
stimulating the therapeutic effect of chemotherapy and diminishing certain side effects. It is
clear that there is a deficient evidence concerning the prospective antioxidant therapies in brain
tumors. Regarding to the fact that there is little knowledge concerning complementary therapy
with antioxidant molecules and their effects or side effects, there is a crucial need for further
research of these treatment strategies.
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